The last time I wrote about Biohaven (NYSE:BHVN) it was with respect to a Seeking Alpha article entitled "Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst."

Biohaven has won Food and Drug Administration priority review for its application seeking approval of troriluzole for adults with spinocerebellar ataxia, a group of rare, genetic neurological ...

Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of adult patients with spinocerebellar ataxia, or SCA ...

NEW HAVEN, Conn. - Biohaven Ltd. (NYSE: BHVN), a biotechnology company with a market capitalization of $3.87 billion, announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for troriluzole,